Nanomedicine strategies for hematological malignancies: what is next?
- 1 October 2014
- journal article
- review article
- Published by Future Medicine Ltd in Nanomedicine
- Vol. 9 (15), 2415-2428
- https://doi.org/10.2217/nnm.14.128
Abstract
The major obstacle in treating cancer depends on the low therapeutic index of most anticancer drugs. The lack of specificity, coupled with the large volumes of distribution, translates into a nonpreferential distribution of anticancer drugs to the tumor. Accordingly, the dose of the anticancer drug that is achievable within tumor is limited, resulting in suboptimal treatment and unwanted toxicity. Nanoparticles applied as drug-delivery systems are submicron-sized (3–200 nm) particles, that can enhance the selectivity of the active drug to cancer cells through a change of its pharmacokinetic profile, while avoiding toxicity in normal cells. This review will discuss the current uses of nanodrugs in hematology, with a focus on the most promising nanoparticles in development for the treatment of hematologic tumors.Keywords
This publication has 73 references indexed in Scilit:
- Multifunctional nanoparticles for multimodal imaging and theragnosisChemical Society Reviews, 2011
- Manufacture of IRDye800CW-coupled Fe3O4 nanoparticles and their applications in cell labeling and in vivo imagingJournal of Nanobiotechnology, 2010
- Multifunctional and stimuli-sensitive pharmaceutical nanocarriersEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Application of nanosized Fe 3 O 4 in anticancer drug carriers with target-orientation and sustained-release propertiesBiomedical Materials, 2007
- Surface Modulation of Magnetic Nanocrystals in the Development of Highly Efficient Magnetic Resonance Probes for Intracellular LabelingJournal of the American Chemical Society, 2005
- In vivo cancer targeting and imaging with semiconductor quantum dotsNature Biotechnology, 2004
- Drug Delivery Systems: Entering the MainstreamScience, 2004
- Amplified DNA Sensing and Immunosensing by the Rotation of Functional Magnetic ParticlesJournal of the American Chemical Society, 2003
- Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumorsCancer, 2001
- Liposomes: Realizing Their PromiseHospital Practice, 1992